1
|
Sebastiani P, Federico A, Morris M, Gurinovich A, Tanaka T, Chandler KB, Andersen SL, Denis G, Costello CE, Ferrucci L, Jennings L, Glass DJ, Monti S, Perls TT. Protein signatures of centenarians and their offspring suggest centenarians age slower than other humans. Aging Cell 2021; 20:e13290. [PMID: 33512769 PMCID: PMC7884029 DOI: 10.1111/acel.13290] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 10/23/2020] [Accepted: 11/14/2020] [Indexed: 12/18/2022] Open
Abstract
Using samples from the New England Centenarian Study (NECS), we sought to characterize the serum proteome of 77 centenarians, 82 centenarians' offspring, and 65 age-matched controls of the offspring (mean ages: 105, 80, and 79 years). We identified 1312 proteins that significantly differ between centenarians and their offspring and controls (FDR < 1%), and two different protein signatures that predict longer survival in centenarians and in younger people. By comparing the centenarian signature with 2 independent proteomic studies of aging, we replicated the association of 484 proteins of aging and we identified two serum protein signatures that are specific of extreme old age. The data suggest that centenarians acquire similar aging signatures as seen in younger cohorts that have short survival periods, suggesting that they do not escape normal aging markers, but rather acquire them much later than usual. For example, centenarian signatures are significantly enriched for senescence-associated secretory phenotypes, consistent with those seen with younger aged individuals, and from this finding, we provide a new list of serum proteins that can be used to measure cellular senescence. Protein co-expression network analysis suggests that a small number of biological drivers may regulate aging and extreme longevity, and that changes in gene regulation may be important to reach extreme old age. This centenarian study thus provides additional signatures that can be used to measure aging and provides specific circulating biomarkers of healthy aging and longevity, suggesting potential mechanisms that could help prolong health and support longevity.
Collapse
Affiliation(s)
- Paola Sebastiani
- Institute for Clinical Research and Health Policy StudiesTufts Medical CenterBostonMAUSA
| | - Anthony Federico
- Bioinformatics ProgramBoston UniversityBostonMAUSA
- Division of Computational BiomedicineDepartment of MedicineBoston University School of MedicineBostonMAUSA
| | - Melody Morris
- Novartis Institutes for Biomedical ResearchCambridgeMAUSA
| | | | - Toshiko Tanaka
- Translational Gerontology BranchNational Institute on AgingBaltimoreMDUSA
| | - Kevin B. Chandler
- Translational Glycobiology InstituteDepartment of Translational MedicineFlorida International UniversityHerbert Wertheim College of MedicineMiamiFLUSA
| | - Stacy L. Andersen
- Geriatric SectionDepartment of MedicineBoston University School of Medicine and Boston Medical CenterBostonMAUSA
| | - Gerald Denis
- Department of MedicineBU‐BMC Cancer CenterBoston University School of MedicineBostonMAUSA
| | - Catherine E. Costello
- Department of BiochemistryCenter for Biomedical Mass SpectrometryBoston University School of MedicineBostonMAUSA
| | - Luigi Ferrucci
- Translational Gerontology BranchNational Institute on AgingBaltimoreMDUSA
| | - Lori Jennings
- Novartis Institutes for Biomedical ResearchCambridgeMAUSA
| | - David J. Glass
- Novartis Institutes for Biomedical ResearchCambridgeMAUSA
- Regeneron PharmaceuticalsTarrytownNYUSA
| | - Stefano Monti
- Bioinformatics ProgramBoston UniversityBostonMAUSA
- Division of Computational BiomedicineDepartment of MedicineBoston University School of MedicineBostonMAUSA
| | - Thomas T. Perls
- Geriatric SectionDepartment of MedicineBoston University School of Medicine and Boston Medical CenterBostonMAUSA
| |
Collapse
|
2
|
Liu X, Huang K, Zhang RJ, Mei D, Zhang B. Isochlorogenic Acid A Attenuates the Progression of Liver Fibrosis Through Regulating HMGB1/TLR4/NF-κB Signaling Pathway. Front Pharmacol 2020; 11:582. [PMID: 32425800 PMCID: PMC7206717 DOI: 10.3389/fphar.2020.00582] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 04/15/2020] [Indexed: 01/17/2023] Open
Abstract
Liver fibrosis, a chronic damage process related to further progression of hepatic cirrhosis, has yet no truly effective treatment. Isochlorogenic acid A (ICQA), isolated from a traditional Chinese herbal medicine named Laggera alata (DC.) Sch.Bip. ex Oliv. (Asteraceae), is proved to exhibit anti-inflammatory, hepatoprotective and antiviral properties. However, the actions of ICQA on liver fibrosis are poorly understood. The purpose of this study was to evaluate the actions of ICQA on liver fibrosis and clarify the underlying mechanism. It was found that ICQA had significant protective actions on liver injury, inflammation as we as fibrosis in rats. Meanwhile, ICQA prevented hepatic stellate cells (HSC) activation, indicated by its inhibitory effect on the overexpression of α-smooth muscle actin (α-SMA). In addition, the reduced fibrosis was found to be associated with the decreased protein expression of high-mobility group box 1 (HMGB1) as well as toll like receptor (TLR) 4. Simultaneously, ICQA can suppress the cytoplasmic translocation of HMGB1 in rat liver. Further investigations indicated that ICQA treatment dramatically attenuated the nuclear translocation of the nuclear factor-kB (NF-κB) p65 and suppressed the hepatic expression of p−IκBα in rats with liver fibrosis. Taken together, our study indicated that ICQA could protect against CCl4-induced liver fibrosis probably through suppressing the HMGB1/TLR4/NF-κB signaling pathways.
Collapse
Affiliation(s)
- Xin Liu
- Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China
| | - Kai Huang
- Drug Clinical Trial Institution, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China
| | - Ru Jiao Zhang
- Health Science Center, Hebei University, Baoding, China
| | - Dan Mei
- Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Bo Zhang
- Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
3
|
Cui X, Qin F, Song L, Wang T, Geng B, Zhang W, Jin L, Wang W, Li S, Tian X, Zhang H, Cai J. Novel Biomarkers for the Precisive Diagnosis and Activity Classification of Takayasu Arteritis. CIRCULATION-GENOMIC AND PRECISION MEDICINE 2020; 12:e002080. [PMID: 30645172 DOI: 10.1161/circgen.117.002080] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Establishing the diagnosis and determining disease activity of Takayasu arteritis (TA) remains challenging. Novel biomarkers might help to solve this problem. METHODS In the screening phase, by using large-scale protein arrays detecting samples from 90 subjects (TA active, 29; TA inactive 31; and controls, 30). In the validation phase, by using enzyme-linked immunosorbent assay (ELISA), potential biomarkers for TA diagnosis, and activity classification were measured in independent cohorts, respectively. RESULTS In the screening phase, 18 cytokines significantly differentially enriched between TA patients and controls and another 15 cytokines significantly differentially enriched between TA patient in active and inactive status were identified (adjusted P<0.05). In the validation phase, TIMP (tissue inhibitor of metalloproteinases)-1 was identified as a specific biomarker for TA diagnosis that a cutoff value of 221.86 μg/L could provide a specificity of 89.58% and a positive predictive value of 0.92. Meanwhile, we found it unreliable to use a single biomarker for TA activity classification. Considering this, we further built a logistic regression model based on multiple cytokines, including CA (cancer antigen) 125, FLRG (follistatin-related protein), IGFBP (insulin-like growth factor-binding protein)-2, CA15-3, GROa (growth-regulated alpha protein), LYVE (lymphatic vessel endothelial hyaluronic acid receptor)-1, ULBP (UL16-binding protein)-2, and CD (cluster of differentiation) 99, with an area under the curve reaching 0.909 for discriminating TA activity status. CONCLUSIONS This study suggested TIMP-1 as a specific biomarker for TA diagnosis with a cutoff value of 221.86 μg/L. Furthermore, we provided a logistic regression model based on 8 biomarkers for the precisive activity classification of TA with an area under the curve of 0.909.
Collapse
Affiliation(s)
- Xiao Cui
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China.,Cardiovascular Disease Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, P.R. China (X.C.)
| | - Fang Qin
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China.,Department of Cardiology, Chongqing Cardiac Arrhythmias Therapeutic Service Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China (F.Q.)
| | - Lei Song
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Tian Wang
- Department of Rheumatology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Disease, Beijing, P.R. China (T.W.)
| | - Bin Geng
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Weili Zhang
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Ling Jin
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Wenjie Wang
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Shuangyue Li
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Xinping Tian
- Department of Rheumatology, Peking Union Medical College Hospital (X.T.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Huimin Zhang
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| | - Jun Cai
- Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Diseases, National Center for Cardiovascular Diseases (X.C., F.Q., L.S., B.G., W.Z., L.J., W.W., S.L., H.Z., J.C.), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, P.R. China
| |
Collapse
|